Upregulation of miR-101-3p Overcomes Ibrutinib Resistance by Targeting ABCC5 in Diffuse Large B-Cell Lymphoma (DLBCL)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Upregulation of miR-101-3p Overcomes Ibrutinib Resistance by Targeting ABCC5 in Diffuse Large B-Cell Lymphoma (DLBCL)

Published:2023 Issue:1 Volume:32 Page:11-20
ISSN:1341-7649
Container-title:Journal of Hard Tissue Biology
language:en
Short-container-title:J. Hard Tissue Biology.

Author:

Liu Mengmeng¹,Gao Hui¹,He Yanxia¹,Sun Xueqing²,Zhang Lili¹

Affiliation:

1. Department of Hematology, Dongying People’s Hospital

2. Department of Clinical Laboratory, Dongying People’s Hospital

Publisher

Society for Hard Tissue Regenerative Biology

Subject

Cell Biology,General Dentistry,Orthopedics and Sports Medicine,Biomaterials,Biochemistry,Medicine (miscellaneous)

Link

https://www.jstage.jst.go.jp/article/jhtb/32/1/32_11/_pdf

Reference43 articles.

1. 1. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO and Staudt LM. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511, 2000

2. 2. Siegel RL, Miller KD and Jemal A. Cancer statistics, 2019. CA Cancer J Clin 69: 7-34, 2019

3. 3. Liu Y and Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol 94: 604-616, 2019

4. 4. Ollila TA and Olszewski AJ. Extranodal diffuse large B cell lymphoma: Molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol 19: 38, 2018

5. 5. Pasqualucci L and Dalla-Favera R. The genetic landscape of diffuse large B-cell lymphoma. Semin Hematol 52: 67-76, 2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overexpression of MRP1/ABCC1, Survivin and BCRP/ABCC2 Predicts the Resistance of Diffuse Large B-Cell Lymphoma to R-CHOP Treatment;Cancers;2023-08-15

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3